Design, synthesis, and biological activities of new thieno[3,2- d]pyrimidines as selective type 4 phosphodiesterase inhibitors

Journal of Medicinal Chemistry

Volumn 41, Issue 21, 1998, Pages 4021-4035

  Crespo, Maria I ^a   Pagès, Lluís ^a   Vega, Armando ^a   Segarra, Victor ^a   López, Manel ^a   Doménech, Teresa ^a   Miralpeix, Montserrat ^a   Beleta, Jordi ^a   Ryder, Hamish ^a   Palacios, José M ^a  

^a Research Center ^*  (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

2 BUTYL 4 CYCLOHEXYLAMINOTHIENO[3,2 D]PYRIMIDINE; PHOSPHODIESTERASE IV INHIBITOR; PYRIMIDINE DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; DRUG ACTIVITY; DRUG DESIGN; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYME ACTIVITY; ENZYME INHIBITION; GUINEA PIG; MALE; NONHUMAN;

EID: 15144354411     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm981012m     Document Type: Article

References (66)

1. A preliminary report was presented at XIVth International Symposium, on Medicinal Chemistry, Maastricht, September 1996, P5.14 and P5.36.
2. Palacios, J. M.; Beleta, J.; Segarra, V. Second Messengers Systems as Targets for New Therapeutic Agents: Focus on Selective Phosphodiesterase Inhibitors. Il Farmaco, 1995, 50, 819-827.
3. Sommer, N.; Löschmann, P. A.; Northoff, G. H.; Weller, M.; Steinbrecher, A.; Steinbach, J. P.; Lichtenfels, R.; Meyermann, R.; Riethmüller, A.; Fontana, A.; Dichgans, J.; Martin, R. The Antidepressant Rolipram Suppresses Cytokine Production and Prevents Autoimmune Encephalomyelitis. Nat. Med. 1995, 1, 244-248.
4. Essayan, D. M.; Kagey-Sobotka, A.; Lichtenstein, L. M.; Huang, S. K. Differential Regulation of Human Antigen-specific Th1 and Th2 Lymphocyte Responses by Isoenzyme Selective Cyclic Nucleotide Phoaphodiesterase Inhibitors. J. Pharmacol. Exp. Ther. 1997, 282, 505-512.
5. Bourne, H. R.; Lichtenstein, L. M.; Melmon, K. L.; Henney, C. S.; Weinstein, Y.; Shearer, G. M. Modulation of Inflammation and Immunity by Cyclic AMP. Science 1974, 184, 19-28.
6. Kammer, G. M. The Adenylate Cyclase-cAMP-Protein Kinase A Pathway and Regulation of the Immune Response. Immunol. Today. 1988, 9, 222-229.
7. Epstein, P. M.; Hachisu, R. Cyclic Nucleotide Phosphodiesterase in Normal and Leukemic Human Lymphocytes and Lymphoblasts. Adv. Cyclic Nucleotide Protein Phosphorylation Res. 1984, 16, 303-24.
8. Klein-Tebbe, J.; Wicht, H.; Gagné, L.; Friese, A.; Schunack, W.; Schudt, C.; Kunkel, G. Inhibition of IgE-Mediated Histamine Release from Human Peripheral Leukocytes by Selective Phosphodiesterase Inhibitors. Agent Actions 1992, 36, 200-206.
9. Chan, S. C.; Reifsnyder, D.; Beavo, J. A.; Hanifin, J. M. Immunochemical Characterisation of the Distinct Monocyte Cyclic AMP-Phosphodiesterase from Patients with Atopic Dermatitis. J. Allergy Clin. Immunol. 1993, 91, 1179-1188.
10. Genain, C. P.; Roberts, T.; Davis, R. L.; Nguyen, M. N.; Uccelli, A.; Faulds, D.; Li, Y.; Hedgpeth, J.; Hauser, S. L. Prevention of Autoimmune Demyelination in Non-Human Primates by a cAMP-Specific Phosphodiesterase Inhibitor, Proc. Natl. Acad. Sci. U.S.A. 1995, 92, 3601-3605.
11. Hopkins, S. J.; Meager, A. Cytokines in Synovial Fluid: II. The Presence of Tumour Necrosis Factor and Interferon. Clin. Exp. Immunol. 1988, 73, 88-92.
12. Saxne, T.; Palladino, M. A. Jr.; Heinegard, D.; Talal, N.; Wollheim, F. A. Detection of Tumour Necrosis Factor a but not Tumour Necrosis Factor β in Rheumatoid Arthritis Synovial Fluid and Serum. Arthritis Rheum. 1988, 31, 1041-1045.
13. Elliott, M. J.; Maini, R. N.; Feldmann, M.; Kalden, J. R.; Antoni, C.; Smolen, J. S.; Leeb, B.; Breedveld, F. C.; Macfarlane, J. D.; Bijl, H.; Woody, J. N. Randomised Double-bind Comparison of Chimeric Monoclonal Antibody to Tumour Necrosis Factor a (cA2) Versus Placebo in Rheumatoid Arthritis. Lancet 1994, 344, 1105-1110.
14. Malaisse, W. J.; Malaisse-Lagae, F.; Mayhew, D. A Possible Role for the Adenylcyclase System in Insulin Secretion. J. Clin. Invest. 1967, 46, 1724-1734.
15. 2+, cAMP and Diacylglycerol. Mol. Cell. Endocrinol. 1990, 70, 119-137.
16. Leibowitz, M. D.; Biswas, C.; Brady, E. J.; Conti, M.; Cullinan, C. A.; Hayes, N. S.; Manganiello, V. C.; Saperstein, R.; Wang, L. H.; Zafian P. T.; Berger, J. A. Novel Insulin Secretagogue Is a Phosphodiesterase Inhibitor. Diabetes 1995, 44, 67-74.
17. Lähdevirta, J.; Maury, C. P.; Teppo A. M.; Repo, H. Elevated Levels of Circulating Cachectin/Tumour Necrosis Factor in Patients with Acquired Immunodeficiency Syndrome. Am. J. Med. 1988, 85, 289-291.
18. Kobayashi, S.; Hamamoto, Y.; Kobayuashi, N.; Yamamoto, N. Serum Level of TNFα in HIV-Infected Individuals. AIDS 1990, 4, 169-170.
19. Lowe III, J. A.; Cheng, J. B. The PDE 4 Family of Calcium-Independent Phosphodiesterases Enzymes, Drugs Future 1992, 17, 799-807.
20. Torphy, T. J.; Livi, G. P.; Christensen, S. B. Novel Phosphodiesterase Inhibitors for the Therapy of Asthma. Drugs News Perspect. 1993, 6, 203-214.
21. Palfreyman, M. N. Phosphodiesterase Type 4 Inhibitors as Antiinflammatory Agents. Drugs Future 1995, 20, 793-804.
22. Glaser, T.; Traber, J. TVX 2706. A New Phosphodiesterase Inhibitor with Antiinflammatory Action. Biochemical Characterization, Agents Actions, 1984, 15, 341-348.
23. Lowe III, J. A.; Archer, R. L.; Chapin, D. S.; Cheng, J. B.; Heiweg, D.; Johnson, J. L.; Koe, B. K.; Lebel, L. A.; Moore, P. F.; Nielsen, J. A.; Russo, L. L.; Shirley, J. T.; Structure-Activity Relationship of Quinazolinedione Inhibitors of Calcium-Independent Phosphodiesterase. J. Med. Chem. 1991, 34, 624-628.
24. (a) Wilhem, R.; Loe, B.; Alvarez, R.; Devens, B.; Fong, A. Pyrido-[2,3-d]pyridazinones as Potent and Selective Type 4 Phosphodiesterase Inhibitors. 8th RSC-SCI Medicinal Chemistry Symposium, Cambridge, 1995, P32.
25. (b) Alvarez, R.; Daniels, D. V.; Shelton, E. R.; Baecker, P. S.; Fong, T. A. T.; Devens, B.; Wilhelm, R.; Eglen, R. M.; Cont, M. An Isoform-Selective Inhibitor of Cyclic AMP-Specific Phosphodiesterase (PDE 4) with Antiinflammatory Properties. In Phosphodiesterase Inhibitors; Schudt, C., Dent, G., Rabe, K. F., Eds.; Academic Press; London, 1996; p 161-171.
26. Alvarez, R.;. Wilhelm, R.; Shelton, E. R.; Daniels, D. V.; Yang, D.; Kelly, K.; Eglen, R. M. Potent and Selective Inhibition of Cyclic AMP Specific Phosphodiesterase (PDE 4) by Structural Analogues of Nitraquazone. Can. J. Physiol. Pharmacol. 1994. 72 (Suppl. 1), Abst. P18.2.11, p 510.
27. Alvarez, R.;. Wilhelm, R.; Shelton, E. R.; Daniels, D. V.; Yang, D.; Kelly, K.; Eglen, R. M. Potent and Selective Inhibition of Cyclic AMP Specific Phosphodiesterase (PDE 4) by Structural Analogues of Nitraquazone. Can. J. Physiol. Pharmacol. 1994. 72 (Suppl. 1), Abst. P18.2.11, p 510.
28. Manabe, H.; Ohnuma, K.; Ichimura, M.; Kawakita, T.; Suzuki, F.; Ohmori, K. Pharmacological Properties of a New Bronchodilator, KF19514. 68th Annual Meeting of the Japanese Pharmacological Society, Nagoya, Japan, 1995, S24-4.
29. Suzuki, F.; Kuroda, T.; Kawakita, T.; Manabe, H.; Kitamura, S.; Ohmori, K.; Ichimura, M.; Kase, H.; Ichikawa, S. New Bronchodilators. 3. Imidazo[4,5-c][1,8]naphthyridin-4(5H)-ones. J. Med. Chem. 1992, 35, 4866-4874.
30. Suzuki, F.; Kuroda, T.; Tamura, T.; Sato, S.; Ohmori, K.; Ichikawa, S. New Antiinflammatory Agents. 2. 5-Phenyl-3H-imidazo[4,5-c][1,8]naphthyridin-4(5H)-ones: A New Class of Nonsteroidal Antiinflammatory Agents with Potent Activity Like Glucocorticoids. J. Med. Chem, 1992, 35, 2863-2870.
31. 3H]Rolipram Binding Activity and their Relationship to Emetic Behaviour in the Ferret. J. Med. Chem. 1996, 39, 120-125.
32. Barnette, M. S. Challenges for Drug Discovery. New Drugs for Asthma-III, Montebello, Quebec, July, 1994.
33. Russo, L. L.; Lebel, L. A.; Koe, B. K. Effects of Selected Phosphodiesterase PDE Inhibitors on Calcium-Independent PDE Activity and Rolipram Binding Sites of Cerebral Cortex. Soc. Neurosci. Abstr. 1987, 13, 903.
34. 3H]Rolipram Binding. J. Med. Chem., 1991, 34, 86-89.
35. 3H]Rolipram Binding Site: 3-Norbornyloxy-4-methoxyphenylmethylene Oxindoles. Bioorg. Med. Chem. Lett. 1995, 5, 1965-1968.
36. 3H]Rolipram Binding Site. Biorg. Med. Chem. Lett. 1995, 5, 1969-1972.
37. Pinto, I. L.; Buckle, D. R.; Readshaw, S. A.; Smith, D. G. The Selective Inhibition of Phosphodiesterase 4 by Benzopyran Derivatives of Rolipram. Bioorg. Med. Chem. Lett. 1993, 3, 1743-1746.
38. t36) Dal Piaz, V.; Giovannoni, M. P.; Castellana, C.; Palacios, J. M.; Beleta, J.; Doménech, T.; Segarra, V. Novel Heterocyclic-Fused Pyridazinones as Potent and Selective Phosphodiesterase 4 Inhibitors. J. Med. Chem. 1997, 40, 1417-1421.
39. Chem-X, version Jan96, Chemical Design Limited, Oxfordshire OX7 5SR, England.
40. Davies, E. K.; Murrall, N. W. How Accurate Does a Force Field Need to Be? Comput. Chem. 1989, 13, 149-156.
41. MOPAC version 6.00 (program no. 506 QCPE, Bloomington, IN).
42. Stewart, J. J. P. MOPAC: A Semiempirical Molecular Orbital Program. J. Comput. Aided Mol. Des. 1990, 4, 1-105.
43. Dewar, M. J. S.; Zoebish, E. G.; Healy, E. F.; Stewart, J. J. P. AM1: A New General Purpose Quantum Mechanical Molecular Model. J. Am. Chem. Soc. 1985, 107, 3902-3909.
44. GRID, version 14, Molecular Discovery Limited, Oxford OX2 9LL, England.
45. Goodford, P. J. A Computational Procedure for Determining Energetically Favorable Binding Sites on Biologically Important Macromolecules. J. Med. Chem. 1985, 28, 849-857.
46. Wade, R. C.; Clark, K. J.; Goodford, P. J. Further Development of Hydrogen Bond Functions for Use in Determining Energetically Favorable Binding Sites on Molecules of Known Structure. 1. Ligand Probe Groups with the Ability To Form Two Hydrogen Bonds. J. Med. Chem. 1993, 36, 140-147.
47. Wade, R. C.; Goodford, P. J. Further Development of Hydrogen Bond Functions for Use in Determining Energetically Favorable Binding Sites on Molecules of Known Structure. 2. Ligand Probe Groups with the Ability To Form More Than Two Hydrogen Bonds. J. Med. Chem. 1993, 36, 148-156.
48. Boobbyer, D. N. A.; Goodford, P. J.; McWhinnie, P. M.; Wade, R. C. New Hydrogen Bond Potentials for Use in Determining Energetically Favorable Binding Sites on Molecules of Known Structure. J. Med. Chem. 1989, 32, 1083-1094.
49. A similar pharmacophore model was simultaneously presented at the XIVth International Symposium on Medicinal Chemistry, Maastrich, September 1996. Polymeropoulos, E. E.; Höfgen, N. A Pharmacophore Model for PDE 4 Inhibitors. P5.44.
50. (a) Mueller, R.; Gebert, L.; Pech, R.; Bohm, R. On Thieno Compounds. Part 17. Preparation of Some New Derivatives of Thieno[2,3-d]pyrimidine. Pharmazie 1993, 48 (8), 585-587.
51. (b) Robba, M.; Lecomte, J. M.; Cugnon de Sévricourt, M. Thienopy- rimidines. I. 4-Oxo-3,4-dihydrothieno[3,2-d]pyrimidine. Bull. Soc. Chim. Fr. 1970, 10, 3630-3636.
52. Robba, M.; Lecomte, J. M.; Cugnon de Sévricourt, M. Thienopyrimidines. II. Thieno-[3,2-d]pyrimidines. Tetrahedron 1971, 27 (2), 487-499.
53. Elderfield, R. C. Heterocyclic Compounds; J. Wiley & Sons: New York, 1957; Vol. 6, pp 324-376.
54. Suzuki, Y.; Yasso, M.; Nishimura, K.; Sacki, K.; Takayanagi, N.; Saito, T.; Hayashi, E. 6-Substituted Alkoxy-2-oxo-1,2-dihydroquinoxaline Derivatives. Eur. Pat. Applic. 311378 A2, 1989 (to Toyo Jozo KK).
55. Janssens, F.; Torremans, J.; Janssen, M.; Stokbroekx. R. A.; Luyckx, M. New Antihistaminic N-Heterocyclic 4-Piperidinamines, 3. Synthesis and Antihistaminic Activity of N-(4-Piperidinyl)-3H-imidazo[4,5-b]pyridin-2-amines. J. Med. Chem. 1985, 28, 1943-1947.
56. Alousi, A. A.; Carter, J. M.; Montenaro, M. J.; Fort, D. J.; Ferrari, R. A. Cardiotonic Activity of Milrinone, a New and Potent Cardiac Bipyridine, on the Normal and Failing Heart of Experimental Animals. J. Cardiovasc. Pharmacol. 1983, 5, 792-803.
57. Barnes, P. J.; Chung, K. F.; Page, C. P. Inflammatory Mediators and Asthma. Pharmacol. Rev. 1988, 40, 49-84.
58. Souness, J. E.; Carter, C. M.; Diocee, B. K.; Hassall, G. A.; Wood, L. J.; Turner, N. C. Characterization of Guinea Pig Eosinophil Phosphodiesterase Activity. Assessment of its Involvement in Regulating Superoxide Generation. Biochem. Pharmacol. 1991, 42, 937-945.
59. Wamser, C. C.; Wagner, W. R. Type II Photoelimination from α-Cycloalkylacetophenones and a Polystyrene-Bound Analog. J. Am. Chem. Soc., 1981, 103 (24), 7232-7234.
60. Barger, G.; Robinson, R.; Smith, L. H. Synthetical Experiments Related to Carpaine, III. Some Derivatives of Tetrahydrofuran and Intermediates of the Aliphatic Series. J. Chem. Soc. 1937, 718-725.
61. Ong-Lee, A.; Sylvester, L.; Wasley, J. W. F. Synthesis of 1,3,4,-14b-Tetrahydro-2H,10H-pyrazino[1,2-α]pyrrolo)[2,1-c][1,4] dibenzoazepines. J. Heterocycl. Chem. 1983, 20, 1565-1569.
62. Andrews, A. F.; Smith, D. M.; Hodson, H. F.; Thorogood, P. B. Synthetic Approaches to Some Aza Analogs of Benzimidazole N-Oxides. Part 1. The Imidazo[4,5-b]pyridine Series. J. Chem. Soc., Perkin Trans. 1 1982, (12), 2995-3006.
63. Shoppee, C. W. Symmetrical Triad Prototropic Systems. IX. The Influence of Polynuclear Aryl Groups upon Mobility and Equilibrium in the α,γ-Diarylmethyleneazomethine System. J. Chem. Soc. 1933, 37-45.
64. Gristwood, R. W.; Beleta, J.; Bou, J.; Cardelus, I.; Fernández, A. G.; Llenas, J.; Berga, P. Studies on the Cardiac Actions of Flosequinan in Vitro. Br. J. Pharmacol. 1992, 105, 985-991.
65. Thompson, W. J.; Strada, S. J.; Cyclic Nucleotide Phosphodiesterase (PDE). In Method of Enzymatic Analysis, 3th ed.; Bergmayer, H. U., Ed.; Verlag-Chemie: Weinheim, 1984; Vol. IV, pp 127-134.
66. Schneider, H. H.; Schmiechen, R.; Brezinski, M.; Seidler, J. Stereospecific Binding of Antidepressant Rolipram to Brain Protein Structures. Eur. J. Pharmacol. 1986, 127, 105-115.